#Netherlands #Drug Delivery #Lupin Limited #Oldenzaal #Nanomi B.V.

Nanomi B.V. Receives CMO Award for Leadership in Drug Delivery

In a significant recognition of its contributions to healthcare, Nanomi B.V., a Dutch subsidiary of the global pharmaceutical giant Lupin Limited, has been awarded the esteemed CMO Award in the field of life sciences at the recent Drug, Chemical and Associated Technologies Association (DCAT) Week held in New York City. This prestigious accolade underscores Nanomi's pioneering innovations in drug delivery systems, which have set new benchmarks within the pharmaceutical industry.

The Chief Scientific Officer of Lupin, Shahin Fesharaki, highlighted the importance of this award during the announcement, stating, “This recognition underscores our unwavering commitment to advancing science and showcases Nanomi’s innovative spirit in drug administration. Our dedication to innovation is aimed at delivering high-quality medications that significantly enhance patient outcomes.” His remarks capture the essence of what the award represents: a validation of hard work, creativity, and strategic foresight in addressing complex healthcare challenges.

Established in 2011, the CMO Leadership Awards are presented by Outsourced Pharma and Life Science Connect, alongside Orientation Marketing. This year marks a milestone as it is the inaugural one where the award was adjudicated by a jury, reflecting the increasing emphasis on qualitative advancements in the industry, rather than quantitative metrics alone.

Nanomi’s approach integrates cutting-edge technology with comprehensive research methodologies to design drug delivery systems that respond to evolving health needs. This focus on innovation has led to the development of solutions that not only improve the effectiveness of therapeutics but also streamline their administration processes.

Lupin Limited is a notable force in the global pharmaceutical landscape, headquartered in Mumbai, India, with its products reaching over 100 markets worldwide. The company specializes in a diverse range of pharmaceuticals, encompassing both brand-name and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Through its innovative commitment, Lupin has earned the trust of health professionals and consumers alike across various therapeutic sectors, including respiratory, cardiovascular, diabetes, and women's health, to name a few.

With state-of-the-art manufacturing facilities and research centers globally, Lupin leverages a dedicated workforce of over 23,000 professionals to continue its mission of enhancing patient health outcomes through innovation. The successful receipt of the CMO Award serves not only as a badge of honor for Nanomi but also as a motivational catalyst for further advancements in their drug delivery capabilities.

For more insights into Nanomi’s groundbreaking work and Lupin’s wide array of pharmaceuticals, readers are encouraged to visit Nanomi and Lupin online, or connect via LinkedIn. With this prestigious award in hand, Nanomi aims to set an even higher standard for excellence in healthcare, inspiring other organizations within the industry to pursue innovation with the same vigor.

This achievement is a testament to the pivotal role that forward-thinking companies like Nanomi play in transforming the landscape of drug delivery and healthcare at large, paving the way for better patient outcomes and more effective treatment methodologies.